GSMA: WRC-19 Opens Door To Exciting New 5G Services
22.11.2019 17:30:00 EET | Business Wire | Press release
The GSMA today welcomed the international spectrum treaty adopted by the World Radiocommunication Conference 2019 (WRC-19), which will unlock the potential for game-changing 5G services around the world. The conference, which has just concluded in Sharm el-Sheikh, Egypt, has identified much-needed spectrum for a broad range of new ultra-high-speed and ultra-low latency consumer, business and government services.
Innovative 5G services that rely on the almost instantaneous delivery of large amounts of data are now possible through the identification of millimetre wave frequencies in the 26 GHz, 40 GHz and 66 GHz ranges. These include virtual and augmented reality applications, remote control of industrial robots, autonomous vehicles, as well as entertainment services, such as downloading 4K movies in seconds.
International coordination supported by the International Telecommunication Union (ITU) at WRCs is essential to achieving widespread spectrum harmonisation for mobile services. The global identification of mmWave frequencies will help unlock economies of scale needed to accelerate the delivery of innovative and affordable 5G services around the world. A wide range of industries – including manufacturing, transport, healthcare and education – are set to benefit.
“WRC-19 has brought the mobile industry a step closer to making the full power of 5G something everyone can experience,” said Mats Granryd, Director General, GSMA. “Countries struck the right balance in opening up groundbreaking possibilities for 5G while protecting existing radio services worldwide. The mobile industry’s goal going into WRC-19 was to identify enough 5G spectrum to deliver long-lasting socio-economic benefits. WRC-19 delivered on this goal, and also secured a pathway to 5G’s future success in the agenda for WRC-23.”
As mobile continues to evolve, so do the spectrum requirements. WRC-19 recognised this by setting an agenda for the next WRC in 2023 that will consider identification of additional mid- and low-frequency bands.
Mid-frequency spectrum in the 3 GHz range (from 3.3-4.2 GHz) is already being used for commercial 5G services, providing a good balance of coverage and capacity. Increasing the amount of globally harmonised spectrum in this frequency range at WRC-23 would boost 5G network performance, bring down deployment costs and drive significant economic benefits.
To help spread the benefits of 5G to rural areas and accelerate the Internet of Things (IoT) revolution, the GSMA is also supporting efforts to identify more spectrum below 1 GHz at WRC-23 to improve 5G coverage.
“We want the benefits of 5G to be available to everyone. With more than 5 billion mobile subscribers globally, previous generations of mobile technology have connected more people more quickly than any technology in history,” added Mats Granryd. “WRC plays an essential role in driving the global economies of scale that allow mobile services to transform people’s lives and national economies.”
-ENDS-
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191122005284/en/
Contact information
Media Contacts:
For the GSMA
Alia Ilyas
+44 (0)7970 637622
ailyas@gsma.com
GSMA Press Office
pressoffice@gsma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
